Tascom타스컴

Quick answers about Tascom

What does Tascom do?

The company develops, manufactures and sells SimplexTAS, a point-of-care in-vitro diagnostic system that combines a analyzer with disposable reagent cartridges to test for conditions such as diabetes, high cholesterol, liver and kidney disease, and infections. The system can run immunological and clinical chemistry tests on whole blood or urine without pre-treatment and is designed for use in settings without trained laboratory staff, such as primary clinics, pharmacies and Korean oriental medicine clinics. Most of its sales are to export distributors and domestic medical device sellers, with overseas sales accounting for most of its revenue.

What is the market cap of Tascom?

The market capitalisation of Tascom was ₩23B at the close on Oct 27, 2026.

Who are the largest shareholders of Tascom?

According to the latest official filings, the largest reported holders are Lee Seong-dong (34.87%, as of Aug 24, 2026); leesongmargaretminsun (34.05%, as of Aug 25, 2026); KAI-Tyon Unicorn Partnership No. 8 (18.59%, as of Apr 30, 2026).

When is the next earnings report from Tascom?

Korean companies rarely announce results dates in advance. Based on when Tascom filed the same report in past years, its next annual results is expected between Mar 18, 2027 and Mar 22, 2027.